Business
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
Advancing Pipeline of Wholly Owned Base Editing Therapeutics with Four Development-stage Programs Expanding Investment in a Broad Portfolio of Potential New
About this update from Beam Therapeutics Inc.
[{"type":"text","content":"Advancing Pipeline of Wholly Owned Base Editing Therapeutics with Four Development-stage Programs Expanding Investment in a Broad Portfolio of Potential New Programs Designed to Extend Reach of Base Editing Medicines North Carolina Manufacturing Facility Open and Operational, Expected to Commence cGMP Operations in Late 2023 Ended Fourth Quarter 2022 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reaffirmed its anticipated upcoming milestones across the company’s hematology, immunology-oncology, and genetic disease portfolios and reported fourth quarter and full year 2022 financial results. “Just five years since our founding, we achieved significant milestones in 2022, having advanced two ex vivo assets – BEAM-101 and BEAM-201 – into clinical-stage development, and two in vivo liver programs – BEAM-301 and BEAM-302 – on a path to regulatory filings,” said John Evans, chief executive officer of Beam. “As we look ahead in 2023, we are focused on the execution of our clinical trials and advancing preclinical work that we expect will support regulatory filings for BEAM-301 and BEAM-302. Importantly, as our confidence in the power and differentiation of our base editing platform grows, we also continue to make important investments in new programs across each of our strategic pillars. This includes our ESCAPE platform in hematology, our next-generation of highly engineered cell therapies in immunology-oncology, and numerous new base editing programs targeting the liver on our own and with our collaborators. I am incredibly excited about the year ahead as we execute our clinical trials and focus on advancing an entirely new class of potentially one-time transformative medicines that could benefit so many patients in need.” Key 2023-2024 Anticipated Milestones and InvestmentsHematology Portfolio Continue enrollment in sentinel cohort of BEACON Phase 1/2 clinical trial evaluating BEAM-101 as a treatment for sickle cell disease (SCD) Finish enrollment in the sentinel cohort in 2023Initiate enrollment in the expansion cohort in 2023Report initial data from multiple patients from one or both cohorts in 2024 Continue to advance and invest...